Publications

Haws, L. Roundtable: Is it Time to Reevaluate the Toxic Equivalency Factors for PCDDs, PCDFs, and Dioxin-Like PCBs? The Use of Toxicity Equivalence Factors (TEFs) for PCDDs, PCDFs, and Dioxin-Like PCBs in Risk Assessment: Improving the Process. Dioxin 2004. September 6-10, 2004. Berlin, Germany.

Haws, L., M. Harris, S. Su, L. Birnbaum, M. DeVito, W. Farland, N. Walker, K. Connor, A.Santamaria, and B. Finley. Development of a refined database of relative potency estimates to facilitate better characterization of variability and uncertainty in the current mammalian TEFs for PCDDs, PDCFs, and dioxin-like PCBs. Dioxin 2004. September 6-10, 2004. Berlin, Germany.

Haws, L., M. Harris, S. Su, N. Walker, L. Birnbaum, M. DeVito, W. Farland, K. Connor, A. Santamaria, and B. Finley. A preliminary approach to characterizing variability and uncertainty in the mammalian PCDD/F and PCB TEFs. Dioxin 2004. September 6-10, 2004. Berlin, Germany.

Perry, C.S. and Morton, E. Lessons learned from creating integrated Excel models to calculate human health screening values. Society for Risk Analysis’ Annual Meeting. December 5-8, 2004. Palm Springs, CA.

Staskal, D.F., J.J. Diliberto, M.J. DeVito, and L.S. Birnbaum. 2004. Tissue distribution and elimination of BDE 47 in mice following a single oral dose.  Dioxin 2004. September 6-10, 2004. Berlin, Germany.

Staskal, D.F., J.J. Diliberto, M.J. DeVito, and L.S. Birnbaum. 2004. Disposition of 2,2’,4,4’-Tetrabromodiphenylether (BDE 47) in Female Mice. 43rd Annual Meeting of Society for Toxicology. March 21-25, 2004. Baltimore, MD.

Urban, J.D., E.A.Gay, and R.B. Mailman. 2004. Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs. 34th Annual Neuroscience Meeting. October 23-27, 2004. San Diego, CA.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. (2004). Effects of prenatal exposure to perfluorooctane sulfonate on the developing lung in the rat. 43rd Annual Meeting of Society for Toxicology. March 21-25, 2004. Baltimore, MD.

Urban, J.D., E.A. Gay, and R.B. Mailman. 2004. Decreased neurological side-effects with aripiprazole: a result of functional selectivity of the D2 receptor? 43rd Annual Meeting of Society for Toxicology. March 21-25, 2004. Baltimore, MD.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. (2004). Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Research, Part A, 70(5), 42.